Peritoneal Metastases in a Patient-derived Orthotopic Xenograft (PDOX) Model of Colon Cancer Imaged Non-invasively via Red Fluorescent Protein Labeled Stromal Cells

Background/Aim: Patient-derived orthotopic xenograft (PDOX) models have patient-like clinical features and may be imaged, in case of some cancers, by passaging of the tumors through transgenic nude mice expressing red-fluorescent protein (RFP) where they stably acquire RFP expressing stroma. The aim of the present study was to quantify red fluorescent area and intensity in colon-cancer peritoneal metastases in PDOX models in non-transgenic nude mice after passage in RFP transgenic nude mice by non-invasive external fluorescence imaging. Materials and Methods: Tumor fragments originating from a colon cancer patient with peritoneal metastases were implanted in transgenic RFP nude mice. Resultant tumors were harvested, and fragments were implanted in the same strain a second time. Passaged tumors stably acquired RFP-expressing stroma from their transgenic hosts. The tumor with RFP-expressing stromal cells were harvested and implanted orthotopically in non-transgenic nude mice. At eight weeks post-implantation, non-invasive external RFP images were obtained. RFP area and intensity were measured and correlated with tumor weight and volume. Results: Metastatic patient colon cancer can be stably and brightly labeled by passage in transgenic RFP-expressing nude mice such that tumor growth could be non-invasively imaged. Tumor growing could be non-invasively imaged when passaged to non-transgenic nude mice. A strong correlation between fluorescence intensity and area values with tumor weight and volume were established by external fluorescence imaging. Conclusion: This new tumor model of metastatic colon cancer can be used to evaluate novel therapeutics in real time for this recalcitrant disease.

[1]  I. Endo,et al.  Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model. , 2019, Biochemical and biophysical research communications.

[2]  M. Bouvet,et al.  Detection of Metastasis in a Patient-derived Orthotopic Xenograft (PDOX) Model of Undifferentiated Pleomorphic Sarcoma with Red Fluorescent Protein , 2018, AntiCancer Research.

[3]  M. Unno,et al.  Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. , 2018, Cancer letters.

[4]  S. Dry,et al.  Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model , 2017, Oncotarget.

[5]  R. Hoffman,et al.  Analysis of Stroma Labeling During Multiple Passage of a Sarcoma Imageable Patient‐Derived Orthotopic Xenograft (iPDOX) in Red Fluorescent Protein Transgenic Nude Mice , 2017, Journal of cellular biochemistry.

[6]  S. Ishihara,et al.  Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer , 2017, Annals of Surgical Oncology.

[7]  R. Hoffman,et al.  Labeling the Stroma of a Patient‐Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft‐Tissue Sarcoma With Red Fluorescent Protein for Rapid Non‐Invasive Imaging for Drug Screening , 2017, Journal of cellular biochemistry.

[8]  A. Govindarajan,et al.  Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy , 2015, Clinics in Colon and Rectal Surgery.

[9]  R. Hoffman Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts , 2015, Nature Reviews Cancer.

[10]  K. Takabe,et al.  Current treatment options for colon cancer peritoneal carcinomatosis. , 2014, World journal of gastroenterology.

[11]  I. Endo,et al.  Efficacy of Salmonella typhimurium A1‐R Versus Chemotherapy on a Pancreatic Cancer Patient‐Derived Orthotopic Xenograft (PDOX) , 2014, Journal of cellular biochemistry.

[12]  M. Bouvet,et al.  Non-invasive fluorescent-protein imaging of orthotopic pancreatic-cancer-patient tumorgraft progression in nude mice. , 2012, Anticancer research.

[13]  J. Coebergh,et al.  Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study , 2011, International journal of cancer.

[14]  M. Hutteman,et al.  Intraoperative near-infrared fluorescence imaging of colorectal metastases targeting integrin α(v)β(3) expression in a syngeneic rat model. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  F. Kwiatkowski,et al.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Robert M Hoffman,et al.  A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. , 2003, The Journal of surgical research.

[18]  Y. Taki,et al.  Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. , 2002, American journal of surgery.

[19]  B. Shmookler,et al.  Peritoneal carcinomatosis from appendiceal cancer: Results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy , 1993, Diseases of the colon and rectum.

[20]  R. Hoffman,et al.  Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Hoffman Patient-Derived Mouse Models of Cancer , 2017, Molecular and Translational Medicine.